

=> b reg

FILE 'REGISTRY' ENTERED AT 11:21:06 ON 11 FEB 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 10 FEB 2004 HIGHEST RN 648858-13-3

DICTIONARY FILE UPDATES: 10 FEB 2004 HIGHEST RN 648858-13-3

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d que stat l2

L1 50 SEA FILE=REGISTRY ABB=ON PLU=ON (YADAIFTNSYRKVLGQLSARKLLQDIMS
RQQGESNQERGARARL)/SQEP

L2 2 SEA FILE=REGISTRY ABB=ON PLU=ON L1 AND C224H366N72O67S/MF

=> d his

(FILE 'HOME' ENTERED AT 11:15:56 ON 11 FEB 2004)

FILE 'REGISTRY' ENTERED AT 11:16:00 ON 11 FEB 2004

E YADAIFTNSYRKVLGQLSARKLLQDIMS RQQGESNQERGARARL/SQEP

L1 50 S E3

L2 2 S L1 AND C224H366N72O67S/MF

FILE 'HCAPLUS' ENTERED AT 11:20:04 ON 11 FEB 2004

L3 2 S L2

FILE 'USPATFULL, USPAT2' ENTERED AT 11:20:15 ON 11 FEB 2004

L4 1 S L2

FILE 'STNGUIDE' ENTERED AT 11:20:38 ON 11 FEB 2004

FILE 'REGISTRY' ENTERED AT 11:21:06 ON 11 FEB 2004

=> d sqide can l2 tot

L2 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2004 ACS on STN

RN 261620-11-5 REGISTRY

CN L-Leucinamide, N-[(3-methylphenyl)acetyl]-L-tyrosyl-L-alanyl-L- α -
aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-asparaginy-
L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucylglycyl-L-glutaminy-
L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminy-
L- α -aspartyl-L-isoleucyl-L-methionyl-L-seryl-L-arginyl-L-glutaminy-
L-glutaminyglycyl-L- α -glutamyl-L-seryl-L-asparaginy-
L-glutaminy-
L- α -glutamyl-L-arginylglycyl-L-alanyl-L-arginyl-L-alanyl-L-arginyl-

(9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE

SQL 44

NTE modified (modifications unspecified)

SEQ 1 YADAIFTNSY RKVLGQLSAR KLLQDIMSRO QGESNQERGA RARL

=====

HITS AT: 1-44

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF C224 H366 N72 O67 S

CI MAN

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:257949

REFERENCE 2: 132:217510

L2 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2004 ACS on STN

RN 261620-06-8 REGISTRY

CN L-Leucinamide, N-[(2-methylphenyl)acetyl]-L-tyrosyl-L-alanyl-L- α -
aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-asparaginyll-L-
seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucylglycyl-L-glutaminyll-L-
leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyll-L-
 α -aspartyl-L-isoleucyl-L-methionyl-L-seryl-L-arginyl-L-glutaminyll-L-
glutaminyllglycyl-L- α -glutamyl-L-seryl-L-asparaginyll-L-glutaminyll-L-
 α -glutamyl-L-arginylglycyl-L-alanyl-L-arginyl-L-alanyl-L-arginyl-
(9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE

SQL 44

NTE modified (modifications unspecified)

SEQ 1 YADAIFTNSY RKVLGQLSAR KLLQDIMSRO QGESNQERGA RARL

=====

HITS AT: 1-44

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF C224 H366 N72 O67 S

CI MAN

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:257949

REFERENCE 2: 132:217510

=> b hcap

FILE 'HCAPLUS' ENTERED AT 11:22:15 ON 11 FEB 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Feb 2004 VOL 140 ISS 7
FILE LAST UPDATED: 10 Feb 2004 (20040210/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> d all tot 13 *Display For HCAPLUS*

L3 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:748783 HCAPLUS
DN 137:257949
ED Entered STN: 03 Oct 2002
TI Growth hormone releasing factor analogs with increased biological potency and their therapeutic uses
IN Gravel, Denis; Habi, Abdelkrim; Brazeau, Paul
PA Theratechnologies Inc., Can.
SO U.S., 32 pp., Cont.-in-part of U. S. 6,020,311.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K038-25
ICS C07K014-60
NCL 514012000
CC 2-2 (Mammalian Hormones)
Section cross-reference(s): 34
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6458764	B1	20021001	US 1999-389486	19990903
	US 5861379	A	19990119	US 1996-702114	19960823
	US 5939386	A	19990817	US 1996-702113	19960823
	US 6020311	A	20000201	US 1998-148982	19980908
	CA 2342070	AA	20000316	CA 1999-2342070	19990907
	WO 2000014236	A2	20000316	WO 1999-CA816	19990907
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9955007	A1	20000327	AU 1999-55007	19990907
	AU 755852	B2	20021219		
	BR 9913515	A	20010605	BR 1999-13515	19990907
	EP 1109909	A2	20010627	EP 1999-941349	19990907
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

	JP 2002524472	T2	20020806	JP 2000-568979	19990907
--	---------------	----	----------	----------------	----------

PRAI US 1995-453067 B2 19950526
 US 1996-651645 B2 19960522
 US 1996-702113 A2 19960823
 US 1996-702114 A2 19960823
 US 1998-148982 A2 19980908
 US 1999-389486 A 19990903
 WO 1999-CA816 W 19990907

AB The present invention relates to chimeric fatty body-GRF analogs with increased biol. potency, their application as anabolic agents and in the diagnosis and treatment of growth hormone deficiencies. The chimeric fatty body-GRF analogs include an hydrophobic moiety (tail), and can be prepared, either by anchoring at least one hydrophobic tail to the GRF, in the chemical synthesis of GRF. The GRF analogs of the present invention are biodegradable, non-immunogenic and exhibit an improved anabolic potency with a reduced dosage and prolonged activity.

ST growth hormone releasing factor analog prepn therapeutic use

IT Proteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (anabolism, improvement of; preparation of growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT Bone, disease
 (fracture, healing of; preparation of growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT Diagnosis
 (of growth hormone deficiencies; preparation of growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT Dwarfism
 (pituitary, treatment; preparation of growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT Antiobesity agents
 Human
 Wound healing
 Wound healing promoters
 (preparation of growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT Growth disorders, animal
 (retarded, treatment; preparation of growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT Pituitary gland, anterior lobe
 (somatotroph, overall upgrading of somatotroph function; preparation of growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT Osteoporosis
 (therapeutic agents; preparation of growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT Obesity
 (treatment; preparation of growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT 9002-72-6, Somatotropin
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (deficiency, treatment; preparation of growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT 9034-39-3DP, Growth hormone releasing factor, analogs
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT 90599-39-6DP, analogs 90830-28-7DP, 1-29-Somatoliberin (human pancreatic

islet), analogs 185744-56-3P 185744-57-4P 261619-10-7P,
 L-Leucinamide, N-[[[(1R,2S)-2-ethylcyclopropyl]acetyl]-L-tyrosyl-L-alanyl-L-
 α -aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-
 asparaginy-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucylglycyl-L-
 glutaminy-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-
 glutaminy-L- α -aspartyl-L-isoleucyl-L-methionyl-L-seryl-L-arginyl-L-
 glutaminy-L-glutaminyglycyl-L- α -glutamyl-L-seryl-L-asparaginy-L-
 glutaminy-L- α -glutamyl-L-arginylglycyl-L-alanyl-L-arginyl-L-alanyl-
 L-arginyl- 261619-56-1P, L-Leucinamide, N-[(cis-2-
 ethylcyclopropyl)acetyl]-L-tyrosyl-L-alanyl-L- α -aspartyl-L-alanyl-L-
 isoleucyl-L-phenylalanyl-L-threonyl-L-asparaginy-L-seryl-L-tyrosyl-L-
 arginy-L-lysyl-L-valyl-L-leucylglycyl-L-glutaminy-L-leucyl-L-seryl-L-
 alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminy-L- α -aspartyl-
 L-isoleucyl-L-methionyl-L-seryl-L-arginyl-L-glutaminy-L-glutaminyglycyl-
 L- α -glutamyl-L-seryl-L-asparaginy-L-glutaminy-L- α -glutamyl-L-
 arginyglycyl-L-alanyl-L-arginyl-L-alanyl-L-arginyl- 261620-00-2P,
 L-Leucinamide, N-[[[(1R,2R)-2-ethylcyclopropyl]acetyl]-L-tyrosyl-L-alanyl-L-
 α -aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-
 asparaginy-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucylglycyl-L-
 glutaminy-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-
 glutaminy-L- α -aspartyl-L-isoleucyl-L-methionyl-L-seryl-L-arginyl-L-
 glutaminy-L-glutaminyglycyl-L- α -glutamyl-L-seryl-L-asparaginy-L-
 glutaminy-L- α -glutamyl-L-arginylglycyl-L-alanyl-L-arginyl-L-alanyl-
 L-arginyl- 261620-02-4P, L-Leucinamide, N-[[[(3R)-3-
 methylcyclopentyl]acetyl]-L-tyrosyl-L-alanyl-L- α -aspartyl-L-alanyl-L-
 isoleucyl-L-phenylalanyl-L-threonyl-L-asparaginy-L-seryl-L-tyrosyl-L-
 arginy-L-lysyl-L-valyl-L-leucylglycyl-L-glutaminy-L-leucyl-L-seryl-L-
 alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminy-L- α -aspartyl-
 L-isoleucyl-L-methionyl-L-seryl-L-arginyl-L-glutaminy-L-glutaminyglycyl-
 L- α -glutamyl-L-seryl-L-asparaginy-L-glutaminy-L- α -glutamyl-L-
 arginyglycyl-L-alanyl-L-arginyl-L-alanyl-L-arginyl- 261620-04-6P,
 L-Leucinamide, N-(bicyclo[4.1.0]hept-1-ylacetyl)-L-tyrosyl-L-alanyl-L-
 α -aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-
 asparaginy-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucylglycyl-L-
 glutaminy-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-
 glutaminy-L- α -aspartyl-L-isoleucyl-L-methionyl-L-seryl-L-arginyl-L-
 glutaminy-L-glutaminyglycyl-L- α -glutamyl-L-seryl-L-asparaginy-L-
 glutaminy-L- α -glutamyl-L-arginylglycyl-L-alanyl-L-arginyl-L-alanyl-
 L-arginyl- 261620-06-8P, L-Leucinamide, N-[(2-
 methylphenyl)acetyl]-L-tyrosyl-L-alanyl-L- α -aspartyl-L-alanyl-L-
 isoleucyl-L-phenylalanyl-L-threonyl-L-asparaginy-L-seryl-L-tyrosyl-L-
 arginy-L-lysyl-L-valyl-L-leucylglycyl-L-glutaminy-L-leucyl-L-seryl-L-
 alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminy-L- α -aspartyl-
 L-isoleucyl-L-methionyl-L-seryl-L-arginyl-L-glutaminy-L-glutaminyglycyl-
 L- α -glutamyl-L-seryl-L-asparaginy-L-glutaminy-L- α -glutamyl-L-
 arginyglycyl-L-alanyl-L-arginyl-L-alanyl-L-arginyl- 261620-11-5P***,
 L-Leucinamide, N-[(3-methylphenyl)acetyl]-L-tyrosyl-L-alanyl-L- α -
 aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-asparaginy-L-
 seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucylglycyl-L-glutaminy-L-
 leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminy-L-
 α -aspartyl-L-isoleucyl-L-methionyl-L-seryl-L-arginyl-L-glutaminy-L-
 glutaminyglycyl-L- α -glutamyl-L-seryl-L-asparaginy-L-glutaminy-L-
 α -glutamyl-L-arginylglycyl-L-alanyl-L-arginyl-L-alanyl-L-arginyl-
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of growth hormone releasing factor analogs with increased biol.
 potency and their therapeutic uses)

IT 75-11-6, Diiodomethane 108-59-8, Dimethyl malonate 108-94-1,
 Cyclohexanone, reactions 111-42-2, Diethanolamine, reactions 121-43-7,

Trimethylborate 124-40-3, Dimethylamine, reactions 593-71-5,
 Chloriodomethane 608-68-4, Dimethyl tartrate 693-03-8, Butyl
 magnesium bromide 867-13-0, Triethylphosphonoacetate 928-96-1,
 cis-3-Hexen-1-ol 928-97-2, trans-3-Hexen-1-ol 6672-30-6,
 Cyclopentanone, 3-methyl-, (3R)- 13368-65-5, Cyclohexanone, 3-methyl-,
 (3R)-

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of growth hormone releasing factor analogs with increased biol.
 potency and their therapeutic uses)

IT 1552-92-7P, Acetic acid, cyclohexylidene-, ethyl ester 4426-47-5P,
 Butylboronic acid 4709-59-5P, 1-Cyclohexene-1-acetic acid, ethyl ester
 24965-94-4P, Cyclohexanol, 3-methyl-, (1R,3R)- 63126-52-3P,
 Butanediamide, 2,3-dihydroxy-N,N,N',N'-tetramethyl-, [S-(R*,R*)]-
 66529-34-8P, Cyclohexanol, 3-methyl-, methanesulfonate, (1R,3R)-
 87626-08-2P, Cyclopropaneacetic acid, 2-ethyl-, (1R,2R)-rel-
 131469-79-9P, Bicyclo[4.1.0]heptane-1-acetic acid 161344-85-0P,
 1,3,2-Dioxaborolane-4,5-dicarboxamide, 2-butyl-N,N,N',N'-tetramethyl-,
 (4R,5R)- 173327-83-8P, Cyclopropaneethanol, 2-ethyl-, (1R,2R)-
 252663-45-9P, Boron, butyl[[2,2'-(imino-κN)bis[ethanolato-
 κO]](2-)]-, (T-4)- 260983-17-3P, Cyclopropaneethanol, 2-ethyl-
 260983-18-4P, Cyclopropaneethanol, 2-ethyl-, (1R,2S)- 260983-19-5P,
 Cyclopropaneacetic acid, 2-ethyl-, (1R,2R)- 260983-20-8P, Acetic acid,
 [(3R)-3-methylcyclopentylidene]-, ethyl ester 260983-21-9P,
 Cyclopentaneacetic acid, 3-methyl-, ethyl ester, (3R)- 260983-22-0P,
 Cyclopentaneacetic acid, 3-methyl-, (3R)- 260983-23-1P,
 Bicyclo[4.1.0]heptane-1-acetic acid, ethyl ester 260983-24-2P,
 Propanedioic acid, [(1S,3R)-3-methylcyclohexyl]-, dimethyl ester
 260983-25-3P, Propanedioic acid, [(1S,3R)-3-methylcyclohexyl]-
 260983-26-4P, Cyclohexaneacetic acid, 3-methyl-, (1S,3R)- 261354-51-2P,
 Cyclopropaneacetic acid, 2-ethyl-, (1R,2S)-

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation of growth hormone releasing factor analogs with increased biol.
 potency and their therapeutic uses)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Brazeau; US 6020311 A 2000 HCAPLUS
- (2) Ibea; US 5861379 A 1999 HCAPLUS
- (3) Ibea; US 5939386 A 1999 HCAPLUS

L3 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2000:175935 HCAPLUS

DN 132:217510

ED Entered STN: 17 Mar 2000

TI Growth hormone releasing factor analogs with increased biological potency
 and their therapeutic uses

IN Gravel, Denis; Habi, Abdelkrim; Brazeau, Paul

PA Theratechnologies Inc., Can.

SO PCT Int. Appl., 81 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C12N015-16

ICS C07K014-60; A61K038-25; G01N033-68

CC 2-10 (Mammalian Hormones)

Section cross-reference(s): 1

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000014236	A2	20000316	WO 1999-CA816	19990907

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6020311 A 20000201 US 1998-148982 19980908

US 6458764 B1 20021001 US 1999-389486 19990903

CA 2342070 AA 20000316 CA 1999-2342070 19990907

AU 9955007 A1 20000327 AU 1999-55007 19990907

AU 755852 B2 20021219

BR 9913515 A 20010605 BR 1999-13515 19990907

EP 1109909 A2 20010627 EP 1999-941349 19990907

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

JP 2002524472 T2 20020806 JP 2000-568979 19990907

PRAI US 1998-148982 A 19980908

US 1999-389486 A 19990903

US 1995-453067 B2 19950526

US 1996-651645 B2 19960522

US 1996-702113 A2 19960823

US 1996-702114 A2 19960823

WO 1999-CA816 W 19990907

OS MARPAT 132:217510

AB The present invention relates to chimeric fatty body-GRF analogs with increased biol. potency, their application as anabolic agents and in the diagnosis and treatment of growth hormone deficiencies. The chimeric fatty body-GRF analogs include a hydrophobic moiety (tail), and can be prepared, either by anchoring at least one hydrophobic tail to the GRF, in the chemical synthesis of GRF. The GRF analogs of the present invention are biodegradable, non-immunogenic and exhibit an improved anabolic potency with a reduced dosage and prolonged activity. Thus, a series of 7 human GRF analogs with a variety of cycloalkyl- or phenyl-containing acyl groups attached to the N-terminus were synthesized. Relative to the human GRF control, these analogs significantly increased insulin-like growth factor 1 (IGF-1) levels in pig serum on day 6. Increased serum IGF-1 levels were observed on day 3 for two of the analogs.

ST growth hormone releasing factor analog

IT Proteins, general, biological studies

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(anabolism; growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT Bone, disease

(fracture, healing of; growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT Antiobesity agents

Wound healing

(growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT Diagnosis

(mol.; growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT Dwarfism

(pituitary, retardation of; growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT Growth, animal

(retardation of; growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT 9034-39-3DP, Growth hormone releasing factor, analogs 185744-56-3P
 185744-57-4P 261619-10-7P 261619-56-1P 261620-00-2P 261620-02-4P
 261620-04-6P 261620-06-8P 261620-11-5P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT 9002-72-6, Growth hormone
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT 75-11-6, Diiodomethane 108-59-8, Dimethyl malonate 108-94-1, Cyclohexanone, reactions 111-42-2, Diethanolamine, reactions 121-43-7, Trimethylborate 124-40-3, Dimethylamine, reactions 593-71-5, Chloriodomethane 608-68-4, Dimethyl tartrate, reactions 693-03-8, Butyl magnesium bromide 867-13-0, Triethylphosphonoacetate 928-96-1, cis-3-Hexen-1-ol 928-97-2, trans-3-Hexen-1-ol 6672-30-6 13368-65-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT 1552-92-7P 4426-47-5P, Butylboronic acid 4709-59-5P 24965-94-4P
 63126-52-3P 66529-34-8P 87626-08-2P 131469-79-9P,
 Bicyclo[4.1.0]heptane-1-acetic acid 161344-85-0P 173327-83-8P
 252663-45-9P 260983-17-3P 260983-18-4P 260983-19-5P 260983-20-8P
 260983-21-9P 260983-22-0P 260983-23-1P 260983-24-2P 260983-25-3P
 260983-26-4P 261354-51-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

IT 90599-39-6 90830-28-7, 1-29-Somatoliberin (human pancreatic islet)
 RL: PRP (Properties)
 (unclaimed protein sequence; growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

=> b uspatall

FILE 'USPATFULL' ENTERED AT 11:22:32 ON 11 FEB 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 11:22:32 ON 11 FEB 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitrn 14 *DISPLAY FOR USPATALL*

L4 ANSWER 1 OF 1 USPATFULL on STN

AN 2002:254337 USPATFULL

TI GRF analogs with increased biological potency

IN Gravel, Denis, St-Lambert, CANADA

Habi, Abdelkrim, Anjou, CANADA

Brazeau, Paul, Montreal, CANADA

PA Theratechnologies Inc., Montreal, CANADA (non-U.S. corporation)

PI US 6458764 B1 20021001

AI US 1999-389486 19990903 (9)

RLI Continuation-in-part of Ser. No. US 1998-148982, filed on 8 Sep 1998, now patented, Pat. No. US 6020311 Continuation-in-part of Ser. No. US

1996-702113, filed on 23 Aug 1996, now patented, Pat. No. US 5939386, issued on 17 Aug 1999 Continuation-in-part of Ser. No. US 1996-702114, filed on 23 Aug 1996, now patented, Pat. No. US 5861379, issued on 19 Jan 1999 Continuation-in-part of Ser. No. US 1996-651645, filed on 22 May 1996, now abandoned Continuation-in-part of Ser. No. US 1995-453067, filed on 26 May 1995, now abandoned

DT Utility

FS GRANTED

EXNAM Primary Examiner: Low, Christopher S. F.; Assistant Examiner: Mohamed, Abdel A.

LREP Crowell & Moring LLP

CLMN Number of Claims: 10

ECL Exemplary Claim: 1

DRWN 10 Drawing Figure(s); 10 Drawing Page(s)

LN.CNT 1550

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB. The present invention relates to chimeric fatty body-GRF analogs with increased biological potency, their application as anabolic agents and in the diagnosis and treatment of growth hormone deficiencies. The chimeric fatty body-GRF analogs include an hydrophobic moiety (tail), and can be prepared, either by anchoring at least one hydrophobic tail to the GRF, in the chemical synthesis of GRF. The GRF analogs of the present invention are biodegradable, non-immunogenic and exhibit an improved anabolic potency with a reduced dosage and prolonged activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 261620-06-8P, L-Leucinamide, N-[(2-methylphenyl)acetyl]-L-tyrosyl-L-alanyl-L- α -aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-asparaginyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucylglycyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L- α -aspartyl-L-isoleucyl-L-methionyl-L-seryl-L-arginyl-L-glutaminyl-L-glutaminylglycyl-L- α -glutamyl-L-seryl-L-asparaginyl-L-glutaminyl-L- α -glutamyl-L-arginylglycyl-L-alanyl-L-arginyl- 261620-11-5P, L-Leucinamide, N-[(3-methylphenyl)acetyl]-L-tyrosyl-L-alanyl-L- α -aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-asparaginyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucylglycyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L- α -aspartyl-L-isoleucyl-L-methionyl-L-seryl-L-arginyl-L-glutaminyl-L-glutaminylglycyl-L- α -glutamyl-L-seryl-L-asparaginyl-L-glutaminyl-L- α -glutamyl-L-arginylglycyl-L-alanyl-L-arginyl-L-alanyl-L-arginyl- (preparation of growth hormone releasing factor analogs with increased biol. potency and their therapeutic uses)

=> b home

FILE 'HOME' ENTERED AT 11:23:34 ON 11 FEB 2004

=>